Abstract: Provided are compositions and methods for treatment of cancer and for adoptive T cell therapy (ACT). The compositions comprise one or more derivatives of tricin 7-O-?-D-glucopyranoside (ANTARTINA®). The compositions comprise one or more pharmaceutically acceptable excipients convenient for delivery of the tricin 7-O-?-D-glucopyranoside derivatives. Tricin 7-O-?-D-glucopyranoside derivatives described herein include acetylated tricin 7-O-?-D-glucopyranoside, as well as glucose, maltose, cellobiose, lactose, xylose, and galactose derivatives. The methods include treatment, or reduction in the risk of suffering from, colorectal cancer and hepatocellular cancer.
Type:
Grant
Filed:
February 14, 2019
Date of Patent:
December 27, 2022
Assignee:
NEOCAGE SL
Inventors:
Manuel Gidekel, Jose Luis Novella Robisco, Mario Nicolas Banduc
Abstract: The present invention belongs to the field of medicine, relates to an inhaled preparation of isoglycyrrhizic acid or a salt thereof, and in particular relates to an inhaled preparation of magnesium isoglycyrrhizinate and the use thereof in preparing drugs for treating respiratory system diseases.
Type:
Grant
Filed:
August 7, 2020
Date of Patent:
December 27, 2022
Assignee:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Abstract: Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided.
Type:
Grant
Filed:
December 8, 2020
Date of Patent:
December 13, 2022
Assignee:
ChromaDex Inc.
Inventors:
Ryan Dellinger, Troy Rhonemus, Mark Morris, Dietrich Conze, Amy Boileau
Abstract: Compositions for the treatment, prevention of, proliferation of, or killing of cells associated with metastatic progression of cancer in a cancer patient are disclosed. More specifically, compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. Compositions disclosed herein include formulations of monolaurin, and formulations including monolaurin and additional components. Also, methods of treating metastatic cancer and/or preventing cancer relapse in a cancer patient by administering compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed.
Abstract: The invention relates to a novel glucose polymer which is particularly useful for administration by the parenteral route, and to the method for the production thereof. The invention also relates to compositions comprising such a glucose polymer, and to the methods for the production thereof. The invention further relates to the use thereof as a medicament, for example as an osmotic agent for peritoneal dialysis.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
November 15, 2022
Assignee:
ROQUETTE FRERES
Inventors:
Denis Simon, Olaf Haeusler, Solène Bock
Abstract: The present invention relates to synergistic bioactive compositions for enhancing cellular energy in aerobic or anaerobic conditions. Particularly, the invention relates to a synergistic bioactive composition comprising specific combination of purine nucleoside and hydrophilic pyridinecarboxamide compound(s) which are present in the ratio of 1:0.1 to 1:1 along with pharmaceutically acceptable carriers/excipients, wherein ‘purine nucleoside’ is inosine adduct and the hydrophilic pyridinecarboxamide compound is selected from nicotinamide riboside or nicotinamide mononucleotide either alone or in combination thereof. Further, the present cellular energy enhancing bioactive compositions are useful for treating ATP deficiency conditions. Moreover, the composition is useful for treating hepatic dysfunctions.
Abstract: A use of a vitamin composition in preparing a drug for preventing, treating, or delaying Alzheimer's disease. The composition comprises a B vitamins composition or an analog or derivative thereof, vitamin C or an analog or derivative thereof, or a combination of a B vitamins composition or an analog or derivative thereof with vitamin C or an analog or derivative thereof.
Abstract: The invention relates generally to the treatment of CYR61- and VEGF-mediated conditions and, more particularly to the treatment of such conditions by administering to an individual a CYR61 downregulator. In one embodiment, the invention provides a method of treating a CYR61-mediated condition in an individual in need of such treatment, the method comprising: administering to the individual an effective amount of at least one CYR61 downregulator (CYR61DR), wherein the effective amount is an amount sufficient to decrease expression of the CYR61 gene in the individual.
Type:
Grant
Filed:
September 4, 2014
Date of Patent:
October 4, 2022
Assignee:
VANDA PHARMACEUTICALS INC.
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: Polyhydric polymers may be converted to derivatives thereof by reaction with divinyl sulfone to provide vinyl sulfone substituted polymers, where the polymers may additionally be further derivatized, including crosslinked, and the crosslinked and non-crosslinked derivatives may be used in biomedical and other applications.
Type:
Grant
Filed:
September 1, 2018
Date of Patent:
September 13, 2022
Assignee:
PMIDG, LLC
Inventors:
David Gravett, Kara Bethany Acampora, Prabhjot Saini
Abstract: Methods and compositions are described for use in encouraging angiogenesis and skin healing as may be utilized in wound treatment as well as in encouragement of angiogenesis in disease. Compositions include an effective amount of at least one of a flavonoid and a chlorogenic acid that are natural extracts of Parrotia persica, or their derivatives, analogues, or homologs. Compounds based upon these natural extracts have been found to be highly effective in vascular formation and skin closure while exhibiting low toxicity.
Type:
Grant
Filed:
September 5, 2018
Date of Patent:
September 13, 2022
Assignee:
University of South Carolina
Inventors:
Ehsan Jabbarzadeh, Sara Eslambolchi Moghadam
Abstract: The present invention has an objective of providing a novel composition for treating a fibrocartilaginous tissue injury. The present invention provides a composition for treating a fibrocartilaginous tissue injury, which is to be applied to an injured fibrocartilaginous tissue part of a target and which comprises a monovalent metal salt of alginic acid, more preferably a low endotoxin monovalent metal salt of alginic acid.
Type:
Grant
Filed:
March 1, 2018
Date of Patent:
August 30, 2022
Assignees:
Mochida Pharmaceutical Co., Ltd., National University Corporation Hokkaido University
Abstract: This invention describes new hydrated and anhydrous polymorphs of 2?-O-fucosyllactose (2?FL): Polymorph A 2?FL-3/2H2O, Polymorph B 2TL-5/2 H2O and anhydrous Polymorph C. There is also a description of the methods for obtaining them, and of a new method for preparing Polymorph I already known in the literature.
Type:
Grant
Filed:
April 24, 2019
Date of Patent:
August 16, 2022
Assignee:
BASF SE
Inventors:
Giovanni Cipolletti, Gessica Laudati, Liana Salsini, Michael Puhl
Abstract: The invention provides a method for the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject, said method comprising administering an effective amount of an alginate oligomer to a subject in need thereof. Also provided is an alginate oligomer for use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject and a product containing an alginate oligomer and further pharmaceutical for the treatment of intestinal microbial overgrowth and/or a CFTR modulator as a combined preparation for separate, simultaneous or sequential use in the treatment or prevention of microbial overgrowth in at least part of the intestinal tract of a subject.
Abstract: The present disclosure, among other things, provides technologies for preparing and purifying phosphoramidites for oligonucleotide synthesis.
Type:
Grant
Filed:
March 13, 2017
Date of Patent:
August 9, 2022
Assignee:
WAVE LIFE SCIENCES LTD.
Inventors:
David Charles Donnell Butler, Subramanian Marappan, Ik-Hyeon Paik
Abstract: Embodiments of the present invention feature a dermal filler comprising a mixture of hyaluronic acid or a pharmaceutically acceptable salt thereof crosslinked with a degree of crosslinking (percent) ranging from 0.5 to 12 in an amount of 0.055 to 2.16% by weight, agarose in an amount between 0.15 to 3.5% agarose by weight and water, sodium chloride, non-gel therapeutic agents, and buffering agents to within a range of ten percent of isotonicity to create a G* value of between 50 and 400.